Scripps nanodisc platform reveals HIV & Ebola epitopes
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Scripps Research Institute unveiled a nanodisc platform, developed with IAVI, that embeds viral glycoproteins into lipid particles to recreate the natural membrane environment.
- Nature Communications published the study on April 12, 2026, showing the platform reveals hidden antibody interactions in HIV and Ebola proteins.
- The nanodisc method cut vaccine candidate analysis time from over a month to about a week, enabling faster comparison of multiple designs.
- HIV antibodies targeting a membrane‑proximal region were found to engage new structural features at the membrane interface, details missed by traditional protein‑only assays.
- Ebola glycoproteins were examined in nanodiscs, confirming that antibodies can bind effectively within a membrane‑like context.
- The platform can be applied to other membrane‑bound viral proteins such as influenza and SARS‑CoV‑2, expanding its utility beyond HIV and Ebola.
- Funding from NIH, the Bill & Melinda Gates Foundation, IAVI, and the Alexander von Humboldt Foundation supported the work.
Why it matters: The platform gives vaccine researchers a realistic view of viral surface proteins, cutting analysis time from weeks to days and exposing membrane‑proximal epitopes that were invisible in traditional assays. This accelerates the design of broadly neutralizing antibodies, potentially improving vaccine efficacy against HIV, Ebola and other membrane‑bound viruses.
